ArticleJournal of addiction medicine2026
Association of Coverage-Promoting Policies With Initiation and Discontinuation of Buprenorphine Treatment During Medicaid Unwinding.
Article in Journal of addiction medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectivesWe examined associations between coverage-promoting policies and changes in initiation and discontinuation of buprenorphine treatment during Medicaid unwinding.
methodsWe conducted a retrospective analysis of national retail pharmacy data (2021-2023) to examine the association between 4 separate coverage-promoting policies and the number of initiations and discontinuations of buprenorphine treatment episodes in the 6 months after unwinding began. Statistical significance was assessed using 2-sample t tests.
resultsFollowing up with enrollees nonresponsive to renewal requests and improving ex parte renewal rates were associated with smaller decreases in initiations (-1.4 percentage point difference [pp] [95% CI: -1.5 to -1.4] and -1.5 pp [95% CI: -1.5 to -1.5], respectively) and smaller increases in discontinuations (0.6 pp [95% CI: 0.5-0.7] and 0.6 pp [95% CI: 0.6-0.7], respectively). Following up on returned mail and mostly automated renewal processing had mixed effects. Following up on returned mail was associated with a larger decrease in initiations (1.1 pp [95% CI: 1.0-1.2]) but a smaller increase in discontinuations (1.1 pp [95% CI: 1.0-1.2]); automated renewal processing was associated with a smaller decrease in initiations (-1.6 pp [95% CI: -1.6 to -1.6]) but a larger increase in discontinuations (-2.5 pp [95% CI: -2.6 to -2.5]).
conclusionsSome coverage-promoting policies were associated with smaller disruptions in buprenorphine treatment during Medicaid unwinding; potential protective effects varied by policy type.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.